BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 19396399)

  • 1. Aptamers against prion proteins and prions.
    Gilch S; Schätzl HM
    Cell Mol Life Sci; 2009 Aug; 66(15):2445-55. PubMed ID: 19396399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenic mutations within the hydrophobic domain of the prion protein lead to the formation of protease-sensitive prion species with increased lethality.
    Coleman BM; Harrison CF; Guo B; Masters CL; Barnham KJ; Lawson VA; Hill AF
    J Virol; 2014 Mar; 88(5):2690-703. PubMed ID: 24352465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide aptamers expressed in the secretory pathway interfere with cellular PrPSc formation.
    Gilch S; Kehler C; Schätzl HM
    J Mol Biol; 2007 Aug; 371(2):362-73. PubMed ID: 17574575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On safari with PrP: prion diseases of animals.
    Westaway D; Carlson GA; Prusiner SB
    Trends Microbiol; 1995 Apr; 3(4):141-7. PubMed ID: 7613755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse prion protein (PrP) segment 100 to 104 regulates conversion of PrP(C) to PrP(Sc) in prion-infected neuroblastoma cells.
    Hara H; Okemoto-Nakamura Y; Shinkai-Ouchi F; Hanada K; Yamakawa Y; Hagiwara K
    J Virol; 2012 May; 86(10):5626-36. PubMed ID: 22398286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights into prion structure and toxicity.
    Harris DA; True HL
    Neuron; 2006 May; 50(3):353-7. PubMed ID: 16675391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of RNAi-mediated prnp gene silencing in neuroblastoma cells permanently infected by prions: potentials and limitations.
    Kim Y; Han B; Titlow W; Mays CE; Kwon M; Ryou C
    Antiviral Res; 2009 Nov; 84(2):185-93. PubMed ID: 19748523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of Peptide Aptamers with Prion Protein Central Domain Promotes α-Cleavage of PrP
    Corda E; Du X; Shim SY; Klein AN; Siltberg-Liberles J; Gilch S
    Mol Neurobiol; 2018 Oct; 55(10):7758-7774. PubMed ID: 29460268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PrP interactions with nucleic acids and glycosaminoglycans in function and disease.
    Silva JL; Gomes MP; Vieira TC; Cordeiro Y
    Front Biosci (Landmark Ed); 2010 Jan; 15(1):132-50. PubMed ID: 20036811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein misfolding cyclic amplification of prions.
    Saunders SE; Bartz JC; Shikiya RA
    J Vis Exp; 2012 Nov; (69):. PubMed ID: 23168797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy in prion diseases: from molecular and cellular biology to therapeutic targets.
    Krammer C; Vorberg I; Schätzl HM; Gilch S
    Infect Disord Drug Targets; 2009 Feb; 9(1):3-14. PubMed ID: 19200010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A transmembrane form of the prion protein in neurodegenerative disease.
    Hegde RS; Mastrianni JA; Scott MR; DeFea KA; Tremblay P; Torchia M; DeArmond SJ; Prusiner SB; Lingappa VR
    Science; 1998 Feb; 279(5352):827-34. PubMed ID: 9452375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for eliminating PrP(c) as substrate for prion conversion and for enhancing PrP(Sc) degradation.
    Gilch S; Nunziante M; Ertmer A; Schätzl HM
    Vet Microbiol; 2007 Aug; 123(4):377-86. PubMed ID: 17493775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of rafts in the fibrillization and aggregation of prions.
    Pinheiro TJ
    Chem Phys Lipids; 2006 Jun; 141(1-2):66-71. PubMed ID: 16647049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discriminating between cellular and misfolded prion protein by using affinity to 9-aminoacridine compounds.
    Phuan PW; Zorn JA; Safar J; Giles K; Prusiner SB; Cohen FE; May BCH
    J Gen Virol; 2007 Apr; 88(Pt 4):1392-1401. PubMed ID: 17374787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virus Infection, Genetic Mutations, and Prion Infection in Prion Protein Conversion.
    Hara H; Sakaguchi S
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prion infection: seeded fibrillization or more?
    Birkmann E; Riesner D
    Prion; 2008; 2(2):67-72. PubMed ID: 19098436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolving views in prion glycosylation: functional and pathological implications.
    Ermonval M; Mouillet-Richard S; Codogno P; Kellermann O; Botti J
    Biochimie; 2003; 85(1-2):33-45. PubMed ID: 12765773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strain-Dependent Prion Infection in Mice Expressing Prion Protein with Deletion of Central Residues 91-106.
    Uchiyama K; Miyata H; Yamaguchi Y; Imamura M; Okazaki M; Pasiana AD; Chida J; Hara H; Atarashi R; Watanabe H; Kondoh G; Sakaguchi S
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity and Architecture of Pathological Prion Protein Assemblies: Time to Revisit the Molecular Basis of the Prion Replication Process?
    Igel-Egalon A; Bohl J; Moudjou M; Herzog L; Reine F; Rezaei H; Béringue V
    Viruses; 2019 May; 11(5):. PubMed ID: 31083283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.